EA200970446A1 - Связывающиеся с альбумином молекулы и их применение - Google Patents

Связывающиеся с альбумином молекулы и их применение

Info

Publication number
EA200970446A1
EA200970446A1 EA200970446A EA200970446A EA200970446A1 EA 200970446 A1 EA200970446 A1 EA 200970446A1 EA 200970446 A EA200970446 A EA 200970446A EA 200970446 A EA200970446 A EA 200970446A EA 200970446 A1 EA200970446 A1 EA 200970446A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
albumin molecules
molecules
agents
albumin
Prior art date
Application number
EA200970446A
Other languages
English (en)
Other versions
EA019335B1 (ru
Inventor
Дарио Нери
Кристоф Думелин
Original Assignee
Филохем Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Филохем Аг filed Critical Филохем Аг
Publication of EA200970446A1 publication Critical patent/EA200970446A1/ru
Publication of EA019335B1 publication Critical patent/EA019335B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к транспортируемым альбуминсвязывающим веществам, которые могут быть использованы для улучшения фармакокинетических свойств диагностических или терапевтических средств, а в частности, для увеличении времени их циркуляции в крови и/или способности таких средств проникать в ткань. Молекулами согласно изобретению являются соединения, представленные формулой (1).
EA200970446A 2006-11-03 2007-11-02 Связывающиеся с альбумином молекулы и их применение EA019335B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0621973.7A GB0621973D0 (en) 2006-11-03 2006-11-03 Binding molecules and uses thereof
PCT/IB2007/004213 WO2008053360A2 (en) 2006-11-03 2007-11-02 Albumin binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
EA200970446A1 true EA200970446A1 (ru) 2009-12-30
EA019335B1 EA019335B1 (ru) 2014-02-28

Family

ID=37547320

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970446A EA019335B1 (ru) 2006-11-03 2007-11-02 Связывающиеся с альбумином молекулы и их применение

Country Status (11)

Country Link
US (1) US8344177B2 (ru)
EP (1) EP2094647B1 (ru)
KR (1) KR20090096599A (ru)
CN (1) CN101668731B (ru)
AU (1) AU2007315788B2 (ru)
BR (1) BRPI0718675A2 (ru)
CA (1) CA2669726C (ru)
EA (1) EA019335B1 (ru)
GB (1) GB0621973D0 (ru)
MX (1) MX2009004705A (ru)
WO (1) WO2008053360A2 (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
WO2010056205A1 (en) 2008-11-11 2010-05-20 Nanyang Technological University Intravascular contrast agents
CN102378576A (zh) * 2009-04-03 2012-03-14 托里度大学 作为药物平台的具有至少一个受保护硫醇区域的peg-白蛋白组合物
US20120134977A1 (en) 2009-06-01 2012-05-31 Yeda Research And Development Co. Ltd. Prodrugs containing albumin binding probe
AU2011343190B2 (en) 2010-12-16 2016-12-08 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
RU2473540C1 (ru) * 2011-06-06 2013-01-27 Федеральное государственное образовательное учреждение высшего профессионального образования Астраханский государственный технический университет (ФГОУ ВПО АГТУ) Амиды 2-(2-гидроксифенилтио)уксусной кислоты, обладающие антиоксидантной активностью, и способ их получения
US20130072854A1 (en) 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
US9273092B2 (en) 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
EP3915369A1 (en) 2012-12-13 2021-12-01 CytRx Corporation Anthracycline formulations
RU2527334C1 (ru) * 2013-05-14 2014-08-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ профилактики и лечения язвенной болезни желудка, вызываемой приемом этанолсодержащих жидкостей
WO2014197569A1 (en) 2013-06-05 2014-12-11 Cytrx Corporation Cytotoxic agents for the treatment of cancer
RS59026B1 (sr) 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
AU2015277494A1 (en) 2014-06-16 2017-01-12 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR102513698B1 (ko) * 2016-06-23 2023-03-23 코넬 유니버시티 종양 사멸에 영향을 주기 위한 이중 표적화 작제물
CN109803973B (zh) 2016-08-10 2022-05-24 癌靶技术有限责任公司 螯合psma抑制剂
CN106366075B (zh) * 2016-08-19 2018-06-12 北京市神经外科研究所 吡咯烷类化合物、盐、核磁探针和药物应用、试剂、药物
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
US11214820B2 (en) * 2016-09-02 2022-01-04 Ikaria Inc. Functionally modified polypeptides and radiobiosynthesis
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法
US11427637B2 (en) 2016-09-06 2022-08-30 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
EP3544960A1 (en) * 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
JP2020530453A (ja) 2017-08-09 2020-10-22 マサチューセッツ インスティテュート オブ テクノロジー アルブミン結合ペプチド結合体及びその方法
TWI804571B (zh) 2018-02-02 2023-06-11 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3094719A1 (en) * 2018-04-05 2019-10-10 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
AU2019398658A1 (en) 2018-12-11 2021-07-29 Sanofi Insulin conjugates
EP3906947A4 (en) * 2019-05-24 2022-07-13 Peking University TARGETED RADIOPHARMACEUTICALS FOR TUMORS AND COMBINATION THERAPY OF TARGETED RADIATION THERAPY THEREOF AND IMMUNOTHERAPY UNDER IMAGE GUIDANCE
KR20220024595A (ko) 2019-06-21 2022-03-03 프로빈셜 헬스 서비시즈 오쏘리티 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물
WO2022040607A1 (en) * 2020-08-20 2022-02-24 Oregon Health & Science University Small molecule albumin binders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
WO1996034012A1 (en) * 1995-04-28 1996-10-31 Takeda Chemical Industries, Ltd. Cyclic pentapeptide lh-rh receptor antagonists
CA2256631A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
US6541203B2 (en) * 1998-11-23 2003-04-01 President And Fellows Of Harvard College Detecting structural or synthetic information about chemical compounds
MXPA04004903A (es) 2001-11-21 2005-06-06 Elan Pharm Inc Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer.

Also Published As

Publication number Publication date
EA019335B1 (ru) 2014-02-28
MX2009004705A (es) 2009-09-07
GB0621973D0 (en) 2006-12-13
CN101668731A (zh) 2010-03-10
US8344177B2 (en) 2013-01-01
KR20090096599A (ko) 2009-09-11
AU2007315788A1 (en) 2008-05-08
CA2669726C (en) 2015-04-07
EP2094647A2 (en) 2009-09-02
WO2008053360A2 (en) 2008-05-08
BRPI0718675A2 (pt) 2013-11-26
AU2007315788B2 (en) 2012-05-24
WO2008053360A3 (en) 2008-06-26
CN101668731B (zh) 2014-11-05
US20100172844A1 (en) 2010-07-08
CA2669726A1 (en) 2008-05-08
EP2094647B1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
EA200970446A1 (ru) Связывающиеся с альбумином молекулы и их применение
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
CY1114617T1 (el) Αμινοτετραϋδροπυρανια ως αναστολεις διπεπτιδυλο πεπτιδασης-iv για την αγωγη ή προληψη διαβητη
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
EA201070422A1 (ru) Производные оксадиазола
EA200802204A1 (ru) Применение ингибиторов dpp iv
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA200971074A1 (ru) Антивирусные соединения
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200870515A1 (ru) Моноциклические гетероарильные соединения
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
ATE445406T1 (de) Verwendung von eisen(iii)-komplexverbindungen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU